erdafitinib

Erdafitinib is an oral, small-molecule, pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. It selectively inhibits the kinase activity of FGFR1, FGFR2, FGFR3, and FGFR4, thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival. Developed by Janssen (Johnson & Johnson) in collaboration with Astex Pharmaceuticals, erdafitinib was the first FGFR inhibitor to receive FDA approval. It is primarily indicated for the treatment of adults with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations that has progressed during or following at least one line of prior platinum-containing chemotherapy. Beyond bladder cancer, erdafitinib has demonstrated clinical activity in other FGFR-driven malignancies, including cholangiocarcinoma and non-small cell lung cancer (NSCLC). It is also being investigated in an intravesical delivery system (TAR-210) for localized bladder cancer.

Brand names

Balversa

Other names

erdafitinib